MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

Completed · Phase 1

Conditions studied: Cancer

In brief

RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid tumors or lymphoma.

Key facts

Study ID

NCT00020579

Run by

National Institutes of Health Clinical Center (CC)

People needed

75

Starts

2001-03-01

Expected to finish

2008-10-01

Last updated by the study team

2012-03-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• National Naval Medical Center — Bethesda, Maryland, United States
• Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support — Bethesda, Maryland, United States
• NCI - Center for Cancer Research — Bethesda, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.